Free US shipping on every order
Early Detection Club field guide
Early detection is moving faster than it has in decades. Blood tests that look for many cancers at once, screening you can do at home, and a new law opening the door to coverage. Here's the whole landscape, from the screening that's proven to the tests being reviewed right now.
Ground height shows how established the evidence is. To the west, screening with strong evidence. To the east, cancers with no screening test yet. In between, the frontier, where new tests are being built and reviewed right now.
Every new kind of test takes the same road: studies, large trials, FDA review, approval, insurance coverage, and finally a place in screening guidelines. Here's where each technology on the frontier stands today, with the companies working on it.
GRAIL, Abbott, Guardant Health, ClearNote Health, Natera, Freenome
Guardant Health, Freenome with Abbott, Epigenomics
Teal Health, Waters with BD, and Roche and BD in clinics
Exact Sciences (Abbott), Geneoscopy
In development
Percentages are hard to feel. Here are the numbers from the research played out across 100,000 people, one dot each.
Picture 100,000 adults over 50 each giving one blood sample for a multi-cancer test. Within a year, about 683 of them are diagnosed with cancer.
The test flags 239 of those cancers from that single draw, and about 6 in 10 positive results turn out to be cancer.
It doesn't flag about 2 in 3 cancers within a year, which is why these tests are studied as an add-on to recommended screening, not a replacement. Built from the FDA's analysis of the largest prospective study of a multi-cancer test.
Specificity is how often people without cancer are correctly told no. Across 100,000 people, a fraction of a percent adds up fast.
At 99.85% specificity, about 149 people get a false alarm, and 62% of positive results are cancer.
In the largest prospective study of a multi-cancer test, specificity was 99.85%. Drag to see how quickly false alarms grow as specificity drops.
For many cancers, the stage at diagnosis changes the odds dramatically. That's the promise the whole frontier is chasing.
Colorectal cancer is found at the localized stage 34% of the time today.
SEER 5-year relative survival, 2016 to 2022. Survival differences by stage partly reflect lead-time bias and overdiagnosis, so they show why early detection is promising rather than proving any one test saves lives.
One blood draw, many cancers. In the FDA's analysis of the largest prospective multi-cancer study, the test detected about 35% of cancers diagnosed within 12 months, with 99.85% specificity, and about 6 in 10 positive results were cancer. Together those figures imply about 683 cancers diagnosed within a year per 100,000 adults 50 and older. Of those, about 239 had a cancer signal detected and 444 didn't. About 149 people without cancer had a signal detected. This is an illustration built from reported figures, not a result from one study population.
Built to rarely cry wolf. False alarms equal the share of people without cancer, multiplied by one minus specificity.
Why early matters. 5-year relative survival by stage at diagnosis, SEER 21, 2016 to 2022. Stage-specific differences partly reflect lead-time bias and overdiagnosis, so they show why early detection is promising, but they aren't by themselves proof that a given screening test saves lives.
Eight years of firsts, and what's expected next.
The full field guide, region by region.
Screening with strong evidence and a USPSTF recommendation. Under the Affordable Care Act, most private plans cover USPSTF A and B screenings without cost-sharing.
USPSTF A and B Ages 45 to 75
More screening options than any other cancer: a camera exam, at-home stool tests, a CT scan, and now a blood test. The starting age moved from 50 to 45 (ACS in 2018, USPSTF in 2021).
USPSTF A Ages 21 to 65
One of screening's great success stories, for a cancer that HPV vaccination can largely prevent. The newest change is that people can collect their own sample.
USPSTF B Every 2 years, 40 to 74
In 2024 the USPSTF moved the start of routine mammograms from 50 to 40. 3D mammography and breast density reporting are changing how screening works.
USPSTF B Yearly low-dose CT, 50 to 80
Low-dose CT screening exists for people with a heavy smoking history. It has the biggest gap of any screening between who's eligible and who gets screened, which makes it one of the biggest opportunities.
USPSTF C Individual decision, 55 to 69
PSA screening is a personal decision made with a clinician. Newer tools, like MRI before a biopsy, are cutting unnecessary biopsies.
USPSTF B Risk assessment and counseling
About 5 to 10% of cancers are linked to inherited gene changes like BRCA1/2 and Lynch syndrome. Knowing about one can change when screening starts and which tests are used.
No-cost for A and B Under the ACA
Most private plans must cover USPSTF A and B screenings, and HRSA women's preventive services, with no cost sharing. That includes the follow-up colonoscopy after a positive stool or blood test.
Sources: 40, 46. Program and coverage details from CDC and HRSA.
Places without a formal screening program, where knowing what's normal and getting changes checked carries the weight.
Not screening Evaluated at any age
Screening is for people without symptoms. A symptom gets evaluated by a clinician whatever someone's age or last screening result.
Source: compiled from ACS and NCI symptom guidance.
USPSTF I Evidence still insufficient
There's no formal skin screening recommendation for people without symptoms. An I statement means the evidence isn't in yet, not "don't." The American Academy of Dermatology encourages regular skin self-exams.
USPSTF D No routine screening
Testicular cancer is rare and highly curable even when found through symptoms, so there's no screening program. Some urology and advocacy groups encourage men to know what's normal for them.
Source: USPSTF testicular cancer screening recommendation (2011, reaffirmed).
Surveillance for specific high-risk groups under specialist care. Not screening for the general population.
Specialist care Li-Fraumeni and others
Some inherited syndromes raise risk across many cancers and come with their own surveillance plans.
Source: compiled from NCCN and USPSTF guidance.
AASLD Every 6 months for high risk
An ultrasound, with or without an AFP blood test, every 6 months for adults with cirrhosis and certain people with chronic hepatitis B.
Source: American Association for the Study of Liver Diseases guidance.
ACG 2022 One-time endoscopy for some
A one-time screening endoscopy is suggested for people with chronic reflux plus 3 or more risk factors.
Source: American College of Gastroenterology guideline (2022).
Expert groups Yearly imaging for high risk
For people at high risk, expert groups support yearly MRI or endoscopic ultrasound at specialized centers.
Source: 53
Expert guidelines 2024 People with HIV
Expert guidelines published in 2024 support anal cancer screening for people with HIV and some other high-risk groups.
Source: compiled from USPSTF and specialty society guidance.
New technology from the last few years, and the tests moving through trials and review right now. Where companies are named, it's to show who's working in a space, and every significant US player in that category is listed.
First FDA decision pending None approved yet
Multi-cancer early detection (MCED) tests look for signals from many cancer types in a single blood draw, including most of the types that have no screening test today. In September 2026 an FDA advisory panel reviewed the first application for one and voted in favor.
Who's building them in the US
Hundreds of companies worldwide are working on blood-based cancer detection. These are the most prominent US efforts.
Sources: 8, 9, 10, 11, 12, 13, 19, 57. Company status compiled from company and FDA announcements, October 2026.
The science Circulating tumor DNA
Tumors shed tiny fragments of DNA into the bloodstream. This circulating tumor DNA is part of the larger pool of cell-free DNA, and blood tests look for signals that set it apart from healthy tissue.
Source: 8
Two FDA-approved for screening Average risk, 45+
Blood tests are now an FDA-approved way to screen for colorectal cancer. The first was approved as a primary screening option in July 2024 and a second in July 2026.
FDA-approved colorectal blood tests
Sources: 20, 21, 22, 34. Second approval compiled from FDA and company announcements, October 2026.
In USPSTF and ACS guidelines Every 1 to 3 years
Molecular stool tests look for cancer-linked DNA or RNA, along with hidden blood, in a sample collected at home. They're one of the listed colorectal screening options.
Who makes molecular stool tests
FDA-approved, at home since 2025 Cervical screening
Self-collection uses a swab or wand to collect a vaginal sample that's tested for high-risk HPV, the cause of nearly all cervical cancers. It can now be done in a clinic or at home.
FDA-authorized self-collection
Sources: 40, 41, 42, 43, 44. HRSA update and April 2026 clearance compiled from federal and company announcements, October 2026.
Widely used Tomosynthesis
Digital breast tomosynthesis builds a layered picture of the breast. It may lower callbacks and find more cancers.
Source: 23
National rule 2024 Every mammogram report
Since September 10, 2024, every US mammography facility has to tell patients whether their breast tissue is dense. Dense tissue makes cancer harder to see on a mammogram and also raises risk.
Smarter biopsies Coverage varies
An MRI before biopsy reduces unnecessary biopsies and the detection of insignificant cancers.
Source: 50
In development Not FDA-approved
Blood-based lung tests are being developed as a way to identify who should get a low-dose CT scan. None is FDA-approved for lung screening.
Source: compiled from published research, October 2026.
Clinician tools FDA-cleared AI
Dermoscopy, a lighted magnifier, improves diagnostic accuracy in trained hands. FDA-cleared AI devices help clinicians assess skin lesions.
Source: 32
Federal research Up to 24,000 people
The National Cancer Institute's Vanguard Study is testing whether a large randomized trial of multi-cancer tests is feasible, a step toward learning whether these tests reduce deaths.
Source: compiled from National Cancer Institute announcements, October 2026.
Signed into law 2026 MCED Act
The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, law since February 3, 2026, creates a Medicare benefit category for FDA-approved multi-cancer tests.
Not supported without symptoms ACR
MRI of most of the body in one session, marketed directly to consumers. It's an established part of surveillance for very high-risk syndromes like Li-Fraumeni, under specialist care.
Who offers whole-body scans
Sources: 55, 56. Providers and prices compiled October 2026.
Consumer tests: limited coverage Genetic risk
Consumer genotyping checks a small, preselected set of known variants and doesn't sequence whole genes. Clinical-grade panels, ordered by a clinician, sequence entire genes across dozens of cancer genes.
Major US labs offering clinical hereditary cancer panels
Sources: 5, 6, 7. Ownership and lab list compiled October 2026.
Cancers with no recommended screening test for people at average risk. Cancer types without a USPSTF A, B, or C screening recommendation account for about 58% of US cancer deaths expected in 2026.
USPSTF D No proven screening test
Large trials of CA-125 blood tests and ultrasound (PLCO and UKCTOCS) didn't reduce deaths. 54% of cases are found at the distant stage.
Source: 54
USPSTF D Average risk
Only about 15% of pancreatic cancers are found at the localized stage, where 5-year survival is 43.6%, versus 3.4% when distant.
Source: 53
USPSTF I Dentists often check
Evidence is insufficient to recommend screening adults without symptoms, though dentists commonly check the mouth at routine visits.
Source: compiled from USPSTF and specialty society guidance.
USPSTF D A lesson in overdiagnosis
When South Korea screened widely with ultrasound, diagnoses of small, harmless tumors surged without reducing deaths. It's the textbook example of why finding more isn't always finding better.
Source: compiled from USPSTF and specialty society guidance.
No routine US screening Average risk
There's no routine US screening for average-risk people. Some groups are evaluated, including CDH1 and Lynch carriers and some higher-risk immigrant groups.
Source: compiled from USPSTF and specialty society guidance.
No screening Average risk
There's no screening for average-risk women. Any bleeding after menopause gets checked promptly, and Lynch carriers have specialist plans.
Source: compiled from USPSTF and specialty society guidance.
No routine screening Average risk
There's no routine screening. Visible blood in the urine gets evaluated.
Source: compiled from USPSTF and specialty society guidance.
Last reviewed October 10, 2026
This page is general information about the field of cancer early detection, gathered from published guidelines, studies, and FDA documents. It isn't medical advice and doesn't speak to anyone's individual situation. Questions about screening are best answered with a clinician.